SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-040785
Filing Date
2021-08-06
Accepted
2021-08-06 16:31:27
Documents
67
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea144854-6k_enlivex.htm   iXBRL 6-K 20516
2 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR ENLIVEX AS OF JUNE 30, ea144854ex99-1_enlivex.htm   iXBRL EX-99.1 452742
3 OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF AND FOR THE THREE AND SIX MON ea144854ex99-2_enlivex.htm EX-99.2 76342
  Complete submission text file 0001213900-21-040785.txt   3847405

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE enlv-20210630.xsd EX-101.SCH 59642
5 XBRL CALCULATION FILE enlv-20210630_cal.xml EX-101.CAL 24279
6 XBRL DEFINITION FILE enlv-20210630_def.xml EX-101.DEF 187407
7 XBRL LABEL FILE enlv-20210630_lab.xml EX-101.LAB 403568
8 XBRL PRESENTATION FILE enlv-20210630_pre.xml EX-101.PRE 199510
9 EXTRACTED XBRL INSTANCE DOCUMENT ea144854-6k_enlivex_htm.xml XML 541227
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36578 | Film No.: 211153366
SIC: 2834 Pharmaceutical Preparations